Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review

Congcong Li 1†, Qing Zhang 1,2†, Siying Zhang 1, Ruifen Dong 1, Chenggong Sun 1, Chunping Qiu 1, Zhiwei Zhang 1, Xingsheng Yang 1 and Beihua Kong 1,2∗

Abstract

Background: 0.17–2% of mature cystic teratoma of the ovary (MCTO) undergo malignant transformation, of which 80% are squamous cell carcinoma (SCC) transformation in MCTO. We aim to investigate the clinical characteristics and treatment of SCC transformation in MCTO.

Methods: We systematically searched PubMed database and individual patient data about SCC transformation in MCTO were extracted. The published cases were combined with 6 cases of SCC transformation in MCTO from Qilu Hospital, Shandong University.

Results: The incidence of SCC transformation in MCTO was 0.3%. A total of 435 cases of SCC transformation in MCTO were enrolled in the analysis. The mean age of diagnosis was 53.5 (range 19–87) years old. The most common clinical manifestations were abdominal pain (47.3%) and abdominal mass (26.0%). Stage I, II, III and IV accounted for 50.0, 18.8, 26.8 and 4.4% of all cases, respectively. Patients with stage I had significantly better prognosis than stage II, III and IV patients (P < 0.01). Hysterectomy can improve overall survival (P < 0.01). For patients younger than 45 years old with stage I or II, there was no difference in mortality between fertility-sparing and radical surgery (P = 1.00). Adjuvant chemotherapy can improve survival in patients with advanced stage (P = 0.02), and chemotherapy with platinum was related to better prognosis (P = 0.02).

Conclusion: SCC transformation in MCTO is a rare malignancy mainly occurs in older age. FIGO stage is an independent prognostic factor. Hysterectomy and platinum-based chemotherapy are associated with better survival. Fertility-sparing surgery is feasible for young patients with early stage.

Keywords: Ovarian cancer, Mature cystic teratoma of the ovary, Squamous cell carcinoma transformation, Survival analysis

Background

Mature cystic teratoma of the ovary (MCTO) may occur in 10–20% of women during their lifetime [1]. The biological behavior of MCTO is benign, while 0.17–2% of MCTO may undergo malignant transformation [2]. There are various histological types of malignant transformation such as squamous cell carcinoma (SCC), adenocarcinoma, small cell carcinoma, sarcoma, malignant melanoma and mixed histology [3]. Among them SCC transformation in MCTO is most common, accounting for 80% of all malignant transformation [4]. The clinical manifestations of SCC transformation in MCTO are not specific. Tumor of early stage is often detected accidentally during physical examination or postoperative pathological examination [5], while palpable mass, bloating and abdominal pain are often present in advanced stage [6, 7]. Acute abdomen may occur due to tumor torsion or rupture [8]. Moreover, preoperative imaging investigation and laboratory tests are not specific, either.
Table 1  Summary data from published literatures on SCC transformation in MCTO

| Country of study | Author (year) | Number of cases | Age | Stage | Grade |
|------------------|---------------|-----------------|-----|-------|-------|
| Japan            | Yoshida et al. (2016) | 2 | 37–64 | I | 1 |
| Japan            | Tazo et al. (2016) | 2 | 45–53 | II | 2 |
| Korea            | Park et al. (2015) | 2 | 48–67 | III | 1 |
| UK               | Araujo et al. (2015) | 4 | 35–44 | IV | 3 |
| China            | Chiang et al. (2015) | 4 | 32–54 | NA | 1 |
| Turkey           | Koc et al. (2015) | 12 | 28–62 | I | 2 |
| USA              | Rojas et al. (2015) | 2 | 55–71 | II | 2 |
| Korea            | Choi et al. (2014) | 4 | 35–51 | III | 1 |
| Pakistan         | Hannan et al. (2014) | 3 | 50–66 | IV | 1 |
| Thailand         | Ornaratanaphan et al. (2013) | 4 | 34–70 | NA | 3 |
| UK               | Powell et al. (2013) | 6 | 42–65 | I | 1 |
| Turkey           | Ulker et al. (2012) | 3 | 43–47 | II | 2 |
| China            | Chiang et al. (2011) | 3 | 32–54 | III | 1 |
| Japan            | Sakuma et al. (2010) | 15 | 29–77 | IV | 1 |
| India            | Gupta et al. (2009) | 2 | 30–65 | I | 1 |
| Korea            | Park et al. (2008) | 12 | 29–75 | II | 2 |
| Japan            | Iwase et al. (2008) | 21 | 32–84 | III | 1 |
| UK               | Hurwitz et al. (2007) | 12 | 27–69 | IV | 1 |
| Japan            | Yamaguchi et al. (2007) | 11 | 29–67 | NA | 3 |
| India            | Bal et al. (2007) | 4 | 35–45 | I | 2 |
| Korea            | Park et al. (2007) | 5 | 31–75 | II | 1 |
| USA              | Dos Santos et al. (2007) | 17 | 37–75 | III | 1 |
| Korea            | Rim et al. (2006) | 7 | 19–71 | IV | 1 |
| China            | Wen et al. (2006) | 2 | 32–52 | I | 1 |
| Thailand         | Tangjitgamol et al. (2003) | 4 | 42–74 | II | 1 |
| Japan            | Sumi et al. (2001) | 3 | 53–72 | III | 1 |
| China            | Chen et al. (2001) | 3 | 30–65 | IV | 1 |
| Japan            | Hirai et al. (2000) | 3 | 61–72 | NA | 3 |
| Japan            | Emoto et al. (2000) | 5 | 39–73 | I | 1 |
| China            | Shen et al. (1998) | 10 | 30–82 | II | 1 |
| Japan            | Yoshioka et al. (1998) | 4 | 41–68 | III | 1 |
| Japan            | Kikkawa et al. (1998) | 37 | 28–87 | IV | 1 |
| China            | Tseng et al. (1996) | 26 | 21–77 | NA | 1 |
| Turkey           | Zorlu et al. (1996) | 3 | 28–42 | I | 1 |
| USA              | Pins et al. (1996) | 16 | 21–75 | II | 1 |
| Japan            | Hirakawa et al. (1989) | 28 | 32–84 | III | 1 |
| Japan            | Kimura et al. (1989) | 6 | 37–80 | IV | 1 |
| Japan            | Kashimura et al. (1989) | 7 | 49–78 | I | 1 |
| Netherlands      | Chadha et al. (1988) | 16 | 35–73 | II | 1 |
| UK               | Ribeiro et al. (1987) | 6 | 25–64 | III | 1 |
| Japan            | Tamaya et al. (1984) | 2 | 30–61 | IV | 1 |
| UK               | Stamp et al. (1983) | 18 | 36–76 | NA | 1 |
### Table 1 Summary data from published literatures on SCC transformation in MCTO (Continued)

| Country of study | Author (year) | Age | Stage | Stage |
|------------------|---------------|-----|-------|-------|
| Australia        | Curling et al. (1979) | 46–73 | 6     | 2     |
| Spain            | Amerigo et al. (1978)  | 42–59 | 2     | 2     |
| USA              | Krumerman et al. (1976) | 51–65 | 2     | 1     |

b. Case reports on SCC transformation in MCTO

| Country of study | Author (year) | Age | Stage | Stage |
|------------------|---------------|-----|-------|-------|
| UK               | Gooneratne et al. (2015) | 63  | II    | 3     |
| USA              | Black et al. (2015)    | 74  | I     | NA    |
| India            | Srivastava et al. (2015) | 60  | II    | 2     |
| Greece           | Kalampokas et al. (2014) | 56  | I     | 1     |
| USA              | Yarmohammadi et al. (2014) | 48  | III   | 3     |
| India            | Patni et al. (2014)    | 53  | I     | NA    |
| Korea            | Yun et al. (2013)      | 30  | I     | 1     |
| Turkey           | Balik et al. (2013)    | 66  | III   | 2     |
| Pakistan         | Chaudhry et al. (2013) | 43  | I     | 2     |
| India            | Mandal et al. (2012)   | 56  | III   | 1     |
| Turkey           | Avci et al. (2012)     | 52  | I     | 2     |
| USA              | Song et al. (2012)     | 73  | II    | 1     |
| Serbia           | Amidzic et al. (2012)  | 80  | I     | 1     |
| USA              | Baughn et al. (2011)   | 58  | I     | NA    |
| Turkey           | Kahraman et al. (2011) | 63  | I     | NA    |
| India            | Prasad et al. (2011)   | 40  | III   | 1     |
| Nigeria          | Badmos et al. (2011)   | 46  | II    | NA    |
| Japan            | Ito et al. (2011)      | 78  | II    | NA    |
| USA              | Parithivel et al. (2011) | 68  | II    | 3     |
| USA              | Alatassi et al. (2011) | 49  | II    | NA    |
| India            | Madan et al. (2010)    | 37  | I     | 1     |
| Greece           | Korkontzelos et al. (2010) | 56  | I     | NA    |
| Japan            | Hosokawa et al. (2010) | 52  | I     | NA    |
| Germany          | Budiman et al. (2010)  | 41  | I     | 3     |
| Korea            | Lim et al. (2009)      | 68  | III   | NA    |
| Iran             | Shariat-Torbaghan et al. (2009) | 63  | IV    | 3     |
| Brazil           | Silva et al. (2009)    | 75  | I     | 1     |
| China            | Wang et al. (2008)     | 39  | III   | 2     |
| China            | Ding et al. (2008)     | 62  | III   | NA    |
| Japan            | Mekaru et al. (2008)   | 33  | I     | NA    |
| India            | Santwani et al. (2008) | 40  | I     | NA    |
| Turkey           | Arioz et al. (2007)    | 31  | II    | 2     |
| UK               | Sanghera et al. (2006) | 48  | II    | NA    |
| Greece           | Filippakis et al. (2006) | 41  | I     | NA    |
| USA              | Spannuth et al. (2005) | 52  | II    | 3     |
| China            | Lai et al. (2005)      | 47  | III   | NA    |
| UK               | Karanjgaokar et al. (2005) | 66  | III   | 2     |
| UK               | Mechery et al. (2004)  | 51  | I     | 3     |
| Japan            | Takemori et al. (2003) | 69  | II    | NA    |
| USA              | Powell et al. (2003)   | 67  | III   | NA    |
Large-scale clinical prospective study is not feasible because of the low incidence of SCC transformation in MCTO and the published cases are scattered, and the optimal treatment for SCC transformation in MCTO remains unclear [9]. Some doctors hold the idea that since SCC originates from epithelium so its treatment should follow principles that of epithelial ovarian cancer [10, 11], some believe that the treatment should refer to SCC of other sites [12], and some suggest that since the malignancy presents on the basis of MCTO, which is a kind of ovarian germ cell tumors, the treatment can refer to that of ovarian germ cell malignancy. However, the surgical principle and postoperative adjuvant therapy of epithelial ovarian cancer, ovarian germ cell tumors and squamous cell carcinoma are different [13]. So it is of great importance to find out the most effective treatment.

| Case | Age (years) | Symptoms | Elevated tumor marker | Diameter (cm) | Surgery | Optimal debulking | Rupture | Grade | Stage | Adjuvant therapy | Follow-up (status, months) |
|------|-------------|----------|-----------------------|---------------|---------|------------------|---------|-------|-------|-----------------|---------------------------|
| 1    | ≥45         | Accidental finding | –                     | 7             | TH + LSO + BPLND + omentectomy | Y       | N     | 3     | IA   | TC × 1                   | LOST, 3                   |
| 2    | ≥45         | Pain      | CA125(179.5 U/mL), CEA (6.1 ng/mL) | 12            | TH + BSO + omentectomy + BPLND + BPALND + peritoneal tumor resection | Y       | N     | 2     | IIB  | TC × 6                   | NED, 72                   |
| 3    | ≥45         | Pain, distension | CA125(363.8 U/mL), CEA (25.2 ng/mL) | 15            | TH + BSO + appendectomy | Y       | N     | 2     | IIIB | TC × 1                   | DOD, 9                    |
| 4    | ≥45         | Pain, distension, fever | CA125(62.9 U/mL), SCC (7.3 ng/mL) | 20            | TH + BSO + omentectomy + partial peritoneal resection | N       | Preoperative | 2     | IIIC | –                        | LOST, 24                  |
| 5    | ≥45         | Pain, vaginal bleeding | CA125(144.7 U/mL), SCC (15.1 ng/mL), CA199(119.1 U/mL), CEA (40.9 ng/mL) | 25            | TH + BSO + tumor resection + sigmoidectomy | N       | Intraoperative | 3     | IIIC | –                        | DOD, 15                   |
| 6    | <45         | Accidental finding | CA125 (428 U/mL), CA199 (97.1 U/mL) | 5             | Initial surgery: Left ovarian cystectomy, Restaging surgery: LSO + omentectomy + BPLND + BPALND | Y       | N     | 3     | IC   | TC × 3                   | NED, 8                    |

TH: total hysterectomy, LSO: left salpingo-oophorectomy, BSO: bilateral salpingo-oophorectomy, BPLND: bilateral pelvic lymph node dissection, BPALND: bilateral para-aortic lymph node dissection, TC: taxol/carboplatin, Y: yes, N: no, DOD: die of disease, NED: no evidence of disease
In this study, we systematically reviewed published data about SCC transformation in MCTO from 1977 to 2016 and cases from Qilu Hospital, Shandong University, aiming to further elucidate the clinical characteristics, prognostic factors, and treatment of SCC transformation in MCTO and provide evidence of clinical management of this rare malignancy.

**Methods**

We searched PubMed database with key words of “squamous cell carcinoma of mature cystic teratoma ovary”, “malignant transformation mature teratoma ovary”, “second tumor teratoma”, “malignant dermoid cyst ovary”, “MCTO squamous cell carcinoma”, “SCC in MCTO”, “mature cystic teratoma malignant”. Cases of SCC transformation in MCTO published from January 1977 to October 2016 were included. Only cases with specific histology, invasive behavior, and available individual patient data were included (Additional file 1: Figure S1). The MCTO cases of Qilu hospital between January 2005 and October 2016 were reviewed and 6 cases of SCC transformation in MCTO were included in this study. Clinicopathologic information, including age, tumor size, symptoms, stage, histological grade, surgical approach, adjuvant therapy, survival status, and follow-up time were collected and analyzed. We used SPSS (version 21.0, for Windows) for statistical analysis. Data analysis was performed with descriptive statistics, chi-square test, Kaplan-Meier plots with Log-rank test, univariate and multivariate Cox proportional hazards regression model. A two-tailed $P<0.05$ value was defined as statistically significant.

**Results**

A total of 435 cases were included in this study, with 429 SCC transformation in MCTO cases from 45 case series and 54 case report [3–8, 10–12, 14–103] (Table 1), and 6 cases from Qilu Hospital, Shandong University.

**Retrospective chart review**

From January 2005 to October 2016, there were 1836 MCTO cases in Qilu Hospital, Shandong University, 6 cases of them were SCC transformation in MCTO, accounting for 0.3% of all MCTO cases. Mean age of the 6 cases was 45.5 years (range: 25–70 years).

**Table 3** Immunohistochemical panel of SCC transformation in MCTO from a retrospective chart review

| Antibody | Source | Dilution | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 |
|----------|--------|----------|--------|--------|--------|--------|--------|--------|
| Ki67     | Abcam  | 1:250    | ++     | ++     | ++     | +++    | ++     | ++     |
| p16      | Abcam  | 1:100    | –       | –       | –       | –       | –       | –       |
| p63      | Abcam  | 1:500    | +       | ++     | ++     | ++     | +       | ++     |
| CK8/18   | Dako   | prediluted | +++      | +++, 5% | ++     | +++    | +++    | +++    |
| CK5/6    | Dako   | prediluted | +++      | ++     | +++    | +++    | +++    | +++    |
| p53      | Abcam  | 1:100    | +, focal | +       | –       | ++     | ++     | +++    |

The antibody reaction was graded according to the intensity of staining: - (negative), + (weak), ++ (moderate), +++ (strong).
patients was 53.7 (range 26–68) years. Follow-up time was 3–72 months. 2 cases underwent comprehensive staging surgery of ovarian cancer. 1 patient received fertility-sparing surgery. For this patient, the diagnosis of SCC transformation in MCTO in stage IC was made after initial left ovarian tumor resection, and then she received fertility-sparing staging surgery. 3 widespread metastatic cases underwent cytoreductive surgery and 1 of them was optimally debulked (residual tumor volume less than 1 cm). 4 cases were treated with postoperative chemotherapy. All of them received TC regimen for 1–6 cycles. No case was treated with postoperative radiotherapy. Details on clinical characteristics were listed in Table 2.

Imaging investigation indicated cystic-solid mass with blood flow signal and enhancement. Grossly, the tumor consisted of cystic and solid components. There were typical components of MCTO such as hair, oil, sebaceous glands and epidermis. Microscopically, there were increased layers of squamous epithelium, disorderly arranged cells, squamous cells with atypia, irregular nuclei and necrosis (Fig. 1). All 6 cases were positive staining for p63, negative staining for p16, moderate to strong positive staining for Ki67 and alteration in p53. Detailed immunohistochemical panel is listed in Table 3 and Fig. 1.

**Systematic review**
Of the 435 cases of SCC transformation in MCTO, follow-up information was available for 363 cases and the follow-up time ranged from 0.4 months to 276 months. 146 (40.2%) cases ended up with death during the follow-up. Mean age of diagnosis was 53.5 (range 19–87) years. 121 (27.9%) were <45 year old while 313 (72.1%) were ≥45 years old (Table 4). Age ≥45 years was related with worse prognosis compared with patients <45 (P < 0.01) (Table 5). Mean tumor size was 14.8 (range 3.5–40.0) cm. Overall survival of tumor ≤10 cm and >10 cm were of no difference (Table 5). Median (Q25, Q75) preoperative SCC-Ag was 7.4 (3.0, 20.0) ng/mL, CA125 was 64.4 (34.2, 143.0) U/mL, CA19–9 was 144.0 (45.1, 943.5) U/mL and CEA was 6.9 (2.5, 23.0) ng/mL. Abdominal pain and palpable abdominal mass were two major clinical manifestations of SCC transformation in MCTO, occurring in 47.3 and 26% of all cases, respectively. Stage I, II, III and IV accounted for 50.0, 18.8, 26.8 and 4.4% of all cases, respectively (Table 4). Compared with stage I, stage II, III and IV were associated with worse prognosis (P < 0.01) (Table 5, Fig. 2a).

### Table 4 Clinical features of SCC transformation in MCTO

| Variable                        | Results             |
|---------------------------------|---------------------|
| Age, years (n = 434)*           | 53.5 (13.9, 19–87)  |
| <45 years                       | 121                 |
| ≥45 years                       | 313                 |
| Tumor size, cm (n = 316)*       | 14.8 (5.9, 3.5–40)  |
| Preoperative tumor markersb     |                     |
| SCC-Ag, ng/mL (n = 78)          | 7.4 (3.0, 20.0)     |
| CA125, U/mL (n = 104)           | 64.4 (34.2, 143.0)  |
| CA19–9, U/mL (n = 65)           | 144.0 (45.1, 943.5) |
| CEA, ng/mL (n = 51)             | 6.9 (2.5, 23.0)     |
| Clinical manifestation (n = 204) |                     |
| Abdominal/pelvic pain           | 139                 |
| Mass                            | 53                  |
| Abdominal bloating              | 49                  |
| Physical examination            | 10                  |
| Urinary frequency               | 6                   |
| Weight loss                     | 11                  |
| Change in bowel habits          | 20                  |
| Fever                           | 7                   |
| FIGO staging (n = 414)          |                     |
| I                               | 207                 |
| II                              | 78                  |
| III                             | 111                 |
| IV                              | 18                  |
| Histological grade (n = 203)    |                     |
| 1                               | 54                  |
| 2                               | 84                  |
| 3                               | 65                  |

*Mean (SD, range); b Median (Q25, Q75)

### Table 5 Clinical features and overall survival of SCC transformation in MCTO

| Variable                        | Univariate HR (95% CI) | P value |
|---------------------------------|------------------------|---------|
| Age, years (n = 370)            |                        |         |
| <45 (n = 105)                   | Reference              |         |
| ≥45 (n = 265)                   | 1.91 (1.26–2.89)       | <0.01*  |
| Diameter (cm) (n = 265)         |                        |         |
| ≤10 (n = 67)                    | Reference              |         |
| >10 (n = 198)                   | 1.08 (0.70–1.68)       | 0.73    |
| Stage (n = 348)                 |                        |         |
| I (n = 172)                     | Reference              |         |
| II (n = 70)                     | 6.92 (3.98–12.06)      | <0.01*  |
| III (n = 92)                    | 9.32 (5.58–15.59)      | <0.01*  |
| IV (n = 14)                     | 16.45 (7.95–34.02)     | <0.01*  |
| Grade (n = 169)                 |                        |         |
| 1 (n = 43)                      | Reference              |         |
| 2 (n = 69)                      | 1.60 (0.81–3.15)       | 0.17    |
| 3 (n = 57)                      | 1.76 (0.89–3.49)       | 0.10    |

Cox proportional hazard regression model analysis

Li et al. BMC Cancer (2019) 19:217 Page 6 of 12
5-year overall survival was 85.8, 39.1, 26.2 and 0% for stage I, II, III, and IV, respectively. There was no interaction between histology grade and survival (Table 5).

As for treatment, hysterectomy can reduce death risk \( (P < 0.01) \) (Table 6, Fig. 2b) whereas lymphadenectomy did not improve survival. Omentectomy did not improve survival with univariate analysis, while after adjusted with International Federation of Gynecology and Obstetrics (FIGO) stage, omentectomy was associated with better prognosis \( (P = 0.04) \) (Table 6). 24 of the 51 patients younger than 45 years old with stage IA or IC underwent fertility-sparing surgery. There was no difference in mortality between fertility-sparing and radical surgery \( (P = 1.00) \).

Efficacy of postoperative adjuvant therapy was analyzed in a subgroup of SCC transformation in MCTO with stage II, III and IV. Adjuvant chemotherapy can improve survival in patients with advanced stage \( (P = 0.02) \) (Table 7, Fig. 2c), and chemotherapy with platinum was related to better prognosis compared with other drugs \( (P = 0.02) \) (Table 8, Fig. 2d). However, radiotherapy and chemoradiotherapy did not improve survival (Table 7).

**Discussion**

SCC transformation in MCTO is the most common malignant transformation of MCTO \[4\] and is also the most common cause of SCC of the ovary \[9, 104\]. SCC transformation in MCTO may be a continuous process of squamous metaplasia, atypical hyperplasia, carcinoma in situ, interstitial infiltration and invasive carcinoma \[14, 105\]. The mean age of MCTO patients without

| Table 6 | Surgery modality and overall survival of SCC transformation in MCTO |
|---------|---------------------------------------------------------------|
| Surgery | Univariate HR (95% CI) | \( P \) value | Stage-adjusted HR (95% CI) | \( P \) value |
| Hysterectomy (325) | | | | |
| Yes (232) vs No (93) | 0.60 (0.42–0.85) | < 0.01* | 0.51 (0.36–0.74) | < 0.01* |
| Lymphadenectomy (325) | | | | |
| Yes (69) vs No (256) | 0.69 (0.43–1.09) | 0.11 | 0.76 (0.47–1.22) | 0.25 |
| Omentectomy (313) | | | | |
| Yes (120) vs No (193) | 1.04 (0.72–1.48) | 0.85 | 0.66 (0.45–0.98) | 0.04 |

\( ^* \) Cox proportional hazard regression model analysis
malignant transformation is 32.7 years [1] while the mean age of SCC transformation in MCTO in our study is 53.5 years. Some cases have a history of MCTO [19, 70], suggesting that unmanaged MCTO may undergo malignant transformation. SCC transformation in MCTO may be associated with high-risk human papilloma virus (HPV) infection [15], and alterations in p53 and p16 may be involved in the process of malignant transformation [16, 17, 106]. A recent next-generation sequencing analysis indicated that TP53 mutation was detected in 80% of SCC transformation in MCTO cases and mutation in TP53 correlated with better prognosis. PIK3CA and CDKN2A were altered in 52 and 44% cases, respectively [107].

In this study, 50% of cases are diagnosed in FIGO stage I. The proportion of stage I is much higher than that of all ovarian cancer, which is 15% [108]. More SCC transformation in MCTO cases can be detected in early stage because the malignant component originates from epithelium of preexistent MCTO [14], which is a gradual process, and is often found unexpectedly after resection of adnexal mass [1]. The same as epithelial ovarian cancer, FIGO stage is an independent prognostic factor for SCC transformation in MCTO. In this study, the 5-year survival rate of stage I patients is 85%, while in patients with stage II, III, the 5-year survival rate is less than 50%. So early detection is of great value and can improve the prognosis of SCC transformation in MCTO.

Comprehensive staging surgery is the standard treatment for ovarian cancer. Hysterectomy and omentectomy appear to improve survival of SCC transformation in MCTO, while lymph node dissection does not affect overall survival in our analysis. This observation suggests that local dissemination is an important metastasis manner of SCC transformation in MCTO. The cases included in this study are retrospective and are from multiple medical centers. What’s more, some cases do not point out the exact scope of lymph node dissection. Since lymph node dissection is part of comprehensive staging surgery, we are in favor of performing lymphadenectomy despite the negative result in this study.

For patients with epithelial ovarian cancer in stages IA/IC, unilateral salpingo-oophorectomy is an optional treatment. For patients with malignant ovarian germ cell tumors, regardless of stage, fertility-sparing surgery can be done and after delivery a comprehensive operation should be conducted [13]. Our study suggests that for SCC transformation in MCTO, it is safe and feasible to perform fertility-sparing surgery in patients younger than 45 years of age old with stage IA/IC. There are cases of successful pregnancies after fertility-sparing surgery [57, 74, 83].

The recommend initial chemotherapy regimen for ovarian germ cell tumor and for epithelial ovarian cancer is bleomycin/etoposide/cisplatin (BEP) and paclitaxel/carboplatin (TC), respectively. Currently there is no recognized first-line adjuvant therapy for SCC transformation in MCTO, though chemotherapy can improve prognosis of patients with SCC transformation in MCTO of advanced stage. Hackethal et al. suggest that chemotherapy with alkylating agents is related to better prognosis in patients with SCC transformation in MCTO.

### Table 7

| Treatment            | Univariate HR (95% CI) | P value | Stage-adjusted HR (95% CI) | P value |
|----------------------|------------------------|---------|-----------------------------|---------|
| Chemotherapy (170)   |                        |         |                             |         |
| Yes (118) vs No (52) | 0.60 (0.40–0.91)       | 0.02*   | 0.56 (0.37–0.86)            | 0.01*   |
| Radiotherapy (170)   |                        |         |                             |         |
| Yes (50) vs No (120) | 0.80 (0.52–1.21)       | 0.29    | 0.89 (0.57–1.38)            | 0.60    |
| Chemoradiotherapy (170) |                    |         |                             |         |
| Yes (31) vs No (139) | 0.71 (0.43–1.16)       | 0.17    | 0.73 (0.44–1.21)            | 0.22    |

**Cox proportional hazard regression model analysis**

### Table 8

| Drug                  | Univariate HR (95% CI) | P value | Stage-adjusted HR (95% CI) | P value |
|-----------------------|------------------------|---------|-----------------------------|---------|
| Platinum derivatives  | 0.43 (0.21–0.87)       | 0.02    | 0.41 (0.20–0.84)            | 0.02    |
| Taxanes               | 1.09 (0.61–1.98)       | 0.78    | 1.10 (0.60–2.00)            | 0.76    |
| Vinca alkaloids       | 0.59 (0.30–1.20)       | 0.14    | 0.48 (0.23–1.01)            | 0.05    |
| Alkylating agents     | 1.05 (0.53–2.09)       | 0.88    | 0.84 (0.38–1.84)            | 0.66    |
| S-FU                  | 0.77 (0.36–1.62)       | 0.50    | 0.82 (0.39–1.75)            | 0.61    |
| Bleomycin             | 0.94 (0.55–1.61)       | 0.82    | 0.85 (0.48–1.50)            | 0.57    |
| VP-16                 | 0.76 (0.33–1.78)       | 0.53    | 0.82 (0.35–1.92)            | 0.64    |

**Cox proportional hazard regression model analysis**
MCTO [109]. However, in our study with the analysis of patients of stage II, III and IV, alkylating agents did not promote overall survival compared with others. We recommend individualized and integrated treatment based on platinum-based chemotherapy.

The histology of SCC transformation in MCTO is squamous cell carcinoma and genetic study indicates that SCC transformation in MCTO has features in common with other SCC [107], which are often sensitive to radiotherapy. However, our results suggested that radiotherapy does not improve prognosis of SCC transformation in MCTO. Whenever applied, doctors should pay attention to complications of radiotherapy [110].

This study has some limitations. Firstly, since the analysis is mostly based on review on published data, we cannot avoid the publication bias. Secondly, although preoperative detection of SCC transformation in MCTO is of great value, in our study we do not conduct the analysis because only a few papers reported the imaging features and serum markers [111, 112]. The size of invasive component, which is possibly related to prognosis, is not available due to the retrospective study design. Moreover, few publications report cycles of chemotherapy, thus we do not investigate the optimal course of treatment. We recommend presentation of such information whenever reporting cases. Lastly, our results should be treated with caution, as the included studies span a prolonged time period (~ 40 years) during which changes in medical and therapeutic strategies may have changed.

Conclusions

SCC transformation in MCTO is a rare malignancy mainly occurs in older age. Early detection is important for better prognosis. Hysterectomy and platinum-based chemotherapy are associated with better survival. Fertility-sparing surgery is feasible for young patients with early stage. Due to the retrospective study design and limited data available, the results should be interpreted with caution. More reports are in need to elucidate the biology of SCC transformation in MCTO.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Clinical Research Center for Gynecological Oncology (2013BAI13805), National Natural Science Foundation of China (81502251), Science and Technology Development Project of Shandong Province (2016GSF10164), National Natural Science Foundation of Shandong Province (BS20145SW009 and 2016ZRJQ2755). The funding sources had no role in the design of this study and will not have any role during collection, analyses, interpretation of the data, or writing the manuscript.

Availability of data and materials

The datasets analyzed during this study are accessible in the PubMed repositories. Data of cases from our institution are available in Table 2.

Authors’ contributions

CL and QZ contributed equally to this work. CL, QZ and BK conceived and designed this study. CL and QZ performed the literature search and study selection. CL, QZ, CQ and ZZ collected all data. SZ, RD and CS performed the immunohistochemistry and summarized the data. CL and QZ contributed to the data analysis and interpretation of results. CL drafted the manuscript. QZ and BK revised the manuscript. CL, QZ, SZ, RD, CS, CQ, ZZ, XY, and BK approved the final version of the manuscript to be published.

Ethics approval and consent to participate

The study was approved by the Ethics Committees of Qilu Hospital, Shandong University. Written informed consent form for publication will be available for every study participant.

Consent for publication

Written informed consent was obtained from the patients.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 February 2018 Accepted: 20 February 2019

Published online: 11 March 2019

References

1. Kim MJ, Kim NY, Lee DY, Yoon BK, Choi D. Clinical characteristics of ovarian teratoma: age-focused retrospective analysis of 580 cases. Am J Obstet Gynecol. 2011;205(1):32.e31–4.
2. Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol. 1994;84(1):32.e31–4.
3. Rim SY, Kim SM, Choi HS. Malignant transformation of ovarian mature cystic teratoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16(1):140–4.
4. Hirakawa T, Tsuchyoshi M, Enjoji M. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis. Am J Surg Pathol. 1989;13(3):397–405.
5. Choi EJ, Koo YJ, Jeon JH, Kim TJ, Lee KH, Lim KT. Clinical experience in ovarian squamous cell carcinoma arising from mature cystic teratoma: a rare entity. Obstetrics & gynecology science. 2014;57(4):274–80.
6. Gooneratne AT, James AO, Gupta J, Abdulla Y. Squamous cell carcinoma arising in a mature cystic teratoma invading the sigmoid colon: a rare presentation. BMJ case reports. 2015;2015:bcr2014208472.
7. Yarmohammadi H, Mansoori B, Wong V, Tacher V, Wilkins LR, Pavlidakes PG, Haaga JR. Squamous cell carcinoma arising from ovarian mature cystic teratoma and causing small bowel obstruction. J Cancer Res Ther. 2014;10(3):770–2.
8. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol. 2008;141(2):173–8.
50. Powell JL, Srinson JA, Connor GP, Shiro BS, Mattison M. Squamous cell carcinoma arising in a dermoid cyst of the ovary. Gynecol Oncol. 2003;89(3):526–8.
51. Mechery J, Adeyemi O. Squamous cell carcinoma arising in a mature teratoma. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 2004;24(2):195–6.
52. Szepehthy WA, Rocconi RP, Kirby TO, Huh WK, Conner MG. Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: a case report. Gynecol Oncol. 2005;98(1):155–7.
53. Lai PF, Hsieh SC, Chien JC, Fang CL, Chan WP, Yu C. Malignant transformation of an ovarian mature cystic teratoma: computed tomography findings. Arch Gynecol Obstet. 2005;271(4):355–7.
54. Karanjgaokar V, Booth AD, Poole DR. Unusual presentation of squamous cell carcinoma in ovarian dermoid. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 2005;25(6):618–8.
55. Sanghera P, El Modir A, Simon J. Malignant transformation within a dermoid cyst: a case report and literature review. Arch Gynecol Obstet. 2006;274(3):178–80.
56. Park SB, Kim JK, Kim KR, Cho KS. Preoperative diagnosis of mature cystic teratoma with malignant transformation: analysis of imaging findings and clinical and laboratory data. Arch Gynecol Obstet. 2007;275(1):25–31.
57. Yun NR, Park JW, Hyun MK, Park JH, Choi SJ, Song E. Squamous cell carcinoma arising in an ovarian mature cystic teratoma complicating pregnancy. Obstetrics & gynecology science. 2013;56(2):579–84.
58. Kalampokas E, Boutas I, Kairi-Vasilatou E, Salakos N, Panoulis K, Aravantinos L. Squamous cell carcinoma in malignant teratoma of the ovary. Acta Obstet Gynecol Scand. 2011;90(7):835–8.
59. Yoshida K, Kajiyama H, Utsumi F, Mitsui H, Shibata K, Kikkawa F. Malignant transformation of ovarian mature cystic teratoma in a postmenopausal woman presented as acute abdomen. Arch Gynecol Obstet. 2010;281(1):177–9.
60. Baughn MR, Plaxe SC, Weidner N. Primary squamous carcinoma of the ovary likely arising from a monodermal cystic mucinous teratoma. Ann Diagn Pathol. 2011;15(6):446–7.
61. Yoshida K, Kajiyama H, Utsumi F, Mitsui H, Shibata K, Kikkawa F. Radiotherapy for persistent malignant transformation from mature cystic teratoma of the ovary. J Obstet Gynaecol Res. 2016.
62. Song W, Conner M. Squamous cell carcinoma arising within a mature cystic teratoma with invasion into the adjacent small intestine: a case report. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists. 2012;31(4):272–5.
63. Hosokawa T, Sato Y, Seki T, Maeba M, Ito K, Kuriyabashi S. Malignant transformation of a mature teratoma of the ovary with rupture. Jpn J Radiol. 2010;28(9):372–5.
64. Lim MC, Jung DC, Park SY. Enterovascular fistula in a patient with a mature cystic cell carcinoma arising in a cystic teratoma. South Med J. 2009;102(5):353–4.
65. Shiratz-Torbaghan S, Ernami-Aleaghia M, Sedighi S, Azadbakh F, Keshvari A, Hajarizadeh B, Rosa J. Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report. Archives of Iranian medicine. 2009;12(186):9.
66. Kahrman K, Cetinkaya SE, Kankaya D, Dunder I, Soylemez F. Squamous cell carcinoma arising from mature cystic teratoma of the ovary with synchronous endometrial adenocarcinoma. J Obstet Gynaecol Res. 2011;37(2):49–54.
67. Hunwitz JL, Fenton A, McCluggage WG, McKenna S. Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series. BJOG: an international journal of obstetrics and gynaecology. 2007;114(10):1283–7.
68. Prasad S, Suguna BV, Ravintra S. Bilateral ovarian squamous cell carcinoma with an antecedent dermoid cyst in the left ovary. J Obstet Gynaecol Res. 2011;37(9):1288–90.
69. Araujo IB, Pinheiro MV, Vanvettor PH, Studart EJ, Filho DF, Coupeland SE. High frequency of malignant transformation of ovarian mature Teratoma into squamous cell carcinoma in Young patients in Northeast Brazil. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists. 2016;35(2):176–84.
70. Wang PC, Yang TL, Pan HB. CT images of a malignant-transformed ovarian mature teratoma with rupture: a case report. Korean J Radiol. 2008;9(5):458–61.
71. Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E. A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2015;25(5):792–7.
72. Budiman HD, Burges A, Ruhl IM, Friese K, Hasbargen U. Squamous cell carcinoma arising in a dermoid cyst of the ovary in pregnancy. Arch Gynecol Obstet. 2010;281(3):535–7.
73. Badmos KB, Ibrahim OK, Aboyeji AP, Omotayo JA. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary with bladder invasion: a case report. Afr Health Sci. 2011;11(2):285–7.
74. Chaudhry S, Hussain R. Squamous cell carcinoma arising in mature cystic teratoma (dermoid cyst)--a rare presentation. JPMFA The Journal of the Pakistan Medical Association. 2013;63(4):521–9.
75. Ito Y, Motokawa S, Kato S, Kajiyama H, Nawa A, Kikkawa F. Carbon ion radiotherapy for recurrent malignant transformation from mature cystic teratoma of the ovary. J Obstet Gynaecol Res. 2012;38(5):880–3.
76. Amidicz J, Dolai M, Kacanski MM, Gluhovic A, Ilic J, Bozanic S. Squamous carcinoma in malignant teratoma of the ovary. Med Pregl. 2012;65(9–10):429–31.
77. Parthivvel K, Jagannathan JP, Krajewski K, O'Regan K, Quick CM, Ramaya N, Campos S. Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer imaging: the official publication of the International Cancer Imaging Society. 2011;11:67–9.
78. Tao Y, Yoshimura Y, Shoda T, Kuysihina N, Okada T, Yamazaki H. Relevance of frozen sections and serum markers in invasive squamous cell carcinoma arising from ovarian mature teratoma: two case reports. J Med Case Rep. 2016;10:20.
79. Ullker V, Numanoglu C, Akbayir O, Akyol A, Tuncel A, Akca A, Aydin O. Malignant transformation arising from mature cystic teratoma of the ovary: a report of six cases. J Obstet Gynaecol Res. 2012;38(8):849–53.
80. Ding DC, Chu TY, Hsu YH. Multimodality therapy of squamous cell carcinoma arising in mature teratoma of the ovary: a case report. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):250–1.
81. Mekanu K, Kamiyama S, Masamoto H, Yagi C, Hirakawa M, Inamine M, Nagai Y, Sakamoto K, Aoki Y. Squamous cell carcinoma arising in an ovarian mature cystic teratoma complicating pregnancy: a case report. Arch Gynecol Obstet. 2008;278(3):287–90.
82. Patir R. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Journal of mid-life health. 2014;5(4):195–7.
83. Srivastava P, Dawson L, Mandal AK. Squamous cell carcinoma arising in mature cystic teratoma with sigmoid invasion. J Cancer Res Ther. 2015;11(4):1024.
84. Santwani PM, Trivedi DP, Vachhani JH, Trivedi NV. Coexistence of squamous cell carcinoma with dermoid cyst of ovary. Indian J Pathol Microbiol. 2008;51(1):81–2.
85. Aoiz DT, Tokoy C, Sahin F, Koker G, Yilmaz S, Yilmazer M, Ozalp S. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary with synchronous invasive lobular breast cancer: a case report. Eur J Gynaecol Oncol. 2008;29(3):282–4.
86. da Silva BB, dos Santos AR, Lopes-Costa PV, Sousa-Junior EC, Correa-Lima MV, Pires CG. Ovarian dermoid cyst with malignant transformation and rupture of the capsule associated with chemical peritonitis: a case report and literature review. Eur J Gynaecol Oncol. 2009;30(2):226–8.
87. Alattasi H, Moghadamfarah M. Squamous cell carcinoma of the rectum, primary or metastatic? Journal of gastrointestinal oncology. 2011;2(4):262–4.
88. Wen KC, Hu WM, Tsu NF, Chen P, Wang PH. Poor prognosis of intraoperative rupture of mature cystic teratoma with malignant transformation. Taiwanese journal of obstetrics & gynecology. 2006;45(3):253–6.
89. Filippakis GM, Lagoudianakis EE, Genetzakis M, Antoniakos P, Papadima A, Boussiotou A, Katergiannakis V, Manouras A. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary with synchronous invasive lobular breast cancer: case report. Eur J Gynaecol Oncol. 2006;27(5):537–40.
90. Christopherson WA, Councill RB. Malignant degeneration of a mature ovarian teratoma. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 1998;30(4):379–84.
93. Kashimura M, Shinohara M, Hirakawa T, Kamura T, Matsukuma K. Clinicopathologic study of squamous cell carcinoma of the ovary. Gynecol Oncol. 1989;34(1):75–9.

94. Kung E, Parham GP. Primary lymphatic dissemination of malignant elements in a mature cystic ovarian teratoma. Gynecol Oncol. 1995;57(2):250–3.

95. Gupta V, Sood N. Squamous cell carcinoma arising in a mature cystic teratoma. Indian J Pathol Microbiol. 2009;52(2):271–3.

96. Hannan A, Awan UE, Siddiqui N, Muzaffar N. Malignant transformations in ovarian teratomas: a report of four cases. JPMJ. Med. Sci. 2014;4(8):946–8.

97. Shen DH, Khoo US, Xue WC, Cheung AN. Ovarian mature cystic teratoma with malignant transformation. An interphase cytogenetic study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1998;17(4):351–7.

98. Stamp GW, McConnell EM. Malignancy arising in cystic ovarian teratomas. A report of 24 cases. Br J Obstet Gynaecol. 1983;90(7):671–5.

99. Bal A, Mohan H, Singh SB, Sehgal A. Malignant transformation in mature cystic teratoma of the ovary: report of five cases and review of the literature. Arch Pathol Lab Med. 2007;131(6):946–82.

100. Krumerman MS, Chung A. Squamous carcinoma arising in benign cystic teratoma of the ovary: a report of four cases and review of the literature. Cancer. 1977;39(3):1237–42.

101. Powell JR, Haldar K. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary – a case series and review of the literature. European Oncology & Haematology. 2013;9(1):17–20.

102. Noumoff JS, LiVolsi VA, Deger RB, Montone KT, Faruqi SA. Chromosome analysis and comparison of the benign cystic and malignant squamous component of an ovarian teratoma. Cancer Genet Cytogenet. 2001;125(1):59–62.

103. Park CH, Jung MH, Ji YI. Risk factors for malignant transformation of mature cystic teratoma. Obstetrics & gynecology science. 2015;58(6):475–80.

104. Nasioudis D, Sisti G, Kanninen TT, Holcomb K, Di Tommaso M, Fambri M, Witkin SS. Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. Gynecol Oncol. 2016;141(1):128–33.

105. Iwasa A, Oda Y, Kaneki E, Ohishi Y, Kurihara S, Yamada T, Hirakawa T, Wake N, Tsuneyoshi M. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: an immunohistochemical analysis of its tumorigenesis. Histopathology. 2007;51(1):98–104.

106. Fujii T, Oguni S, Kikuchi M, Kanai N, Saito K. p53 mutation in carcinomas arising in ovarian cystic teratomas. Pathol Int. 1995;45(9):649–54.

107. Cooke SL, Ennis D, Evers L, Dowson S, Chan MY, Paul J, Hirschowitz L, Glasspool RM, Singh N, Bell S, et al. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Aising in Mature Cystic Teratoma. Clin Cancer Res. 2017;23(24):7633–7640.

108. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

109. Hackethal A, Bruegmann D, Bohlmann MK, Franke FE, Tinneberg HR, Munstedt K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. The Lancet Oncology. 2008;9(12):1173–80.

110. Lim SC, Choi SJ, Suh CH. A case of small cell carcinoma arising in a mature cystic teratoma of the ovary. Pathol Int. 1998;48(10):834–9.

111. Mori Y, Nishi H, Takabe K, Shinozaki H, Matsumoto N, Suzuki K, Tanabe H, Watanabe A, Ochiai K, Tanaka T. Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary. Gynecol Oncol. 2003;90(2):338–41.

112. Zissin R. CT diagnosis of malignant degeneration of an ovarian teratoma. Gynecol Oncol. 2000;77(3):482.